China News Service, Shanghai, June 24th (Chen Jing and Wang Yihui) Non-small cell lung cancer accounts for 85% of all lung cancers and is the most common subtype of lung cancer.

Advanced non-small cell lung cancer patients with EGFR gene mutation can reach more than 50% in Asian population.

How to delay and solve the drug resistance problem of related patients is a hot spot and focus of current lung cancer patients and academia.

  The reporter learned on the 24th that the latest research by Chinese medical experts found that for patients with EGFR-mutated non-small cell lung cancer with oligometastases, receiving high-efficiency, low-toxicity, short-term and fast stereotactic radiotherapy combined with related inhibitor therapy is more effective than receiving simple inhibitor drug therapy. , can prolong the median survival of about 6 months.

Before inhibitor resistance, stereotactic radiotherapy for oligometastatic lesions in the brain also has the potential to prolong patient survival and improve quality of life.

  The so-called oligometastasis refers to a single organ to which a malignant tumor metastasizes and only 1-5 metastases.

"For the treatment of these patients, the conventional therapy is the use of EGFR inhibitors, which are highly efficient and low-toxic, but face the drawback that drug resistance will appear soon after use." Professor Zhu Zhengfei, an expert at the Radiation Therapy Center of Fudan University Affiliated Cancer Hospital, accepted that day. During the interview, he told reporters that drug resistance has become a "bottleneck" restricting the efficacy and survival benefits of these patients, which needs to be solved urgently.

  It is understood that since 2016, the team led by Professor Zhu Zhengfei has carried out a series of explorations on patients with advanced non-small cell lung cancer oligometastases and brain metastases through large-scale multi-center clinical research.

Talking about the selection of non-small cell lung cancer patients with oligometastases and brain metastases as research subjects, Professor Zhu Zhengfei told reporters: "The incidence of oligometastases and brain metastases throughout the course of the disease accounts for 30%-50% of advanced EGFR-mutated non-small cell lung cancers. More than %; moreover, these two groups are expected to achieve long-term survival through aggressive and precise radiation therapy combined with targeted therapy."

  The series of research results have been published in the International Journal of Radiation Oncology Biology Physics, the official journal of the American Society for Radiation Oncology, the International Journal of Cancer, the official journal of the International Alliance against Cancer, and the well-known journals in the field of oncology, Clinical and Translational Medicine, and Lung Cancer. Published in the famous magazine "British Journal of Radiology".

The research team has published more than ten SCI papers.

  At the 2nd Asian Society of Oncology Annual Meeting and the 48th Korean Cancer Association (KCA) Annual Meeting/8th International Cancer Congress, Professor Zhu Zhengfei, as an expert in the field of radiotherapy in China, gave a speech entitled "Radiation therapy in EGFR-mutated advanced non-small cell lung cancer Clinical value in therapy" report.

The chairperson of the meeting, Professor Young Tae Kim of Seoul National University School of Medicine, fully affirmed and spoke highly of "The series of studies carried out by Professor Zhu Zhengfei's team have laid a solid foundation for the optimization of comprehensive treatment of advanced EGFR-mutated non-small cell lung cancer." (End)